Amgen Inc. (BIT:1AMGN)

Market Cap	166.37B +14.9%
Revenue (ttm)	31.30B +10.0%
Net Income	6.57B +88.5%
EPS	12.12 +88.2%
Shares Out	n/a
PE Ratio	25.33
Forward PE	16.34
Dividend	6.23 (2.01%)
Ex-Dividend Date	Nov 20, 2025

Volume	103
Average Volume	54
Open	308.55
Previous Close	307.52
Day's Range	305.05 - 309.60
52-Week Range	230.90 - 324.15
Beta	n/a
RSI	63.04
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1AMGN

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD